K-bio companies are targeting metabolic dysfunction-associated steatohepatitis (MASH) treatments as the next growth driver ...

D&D Pharmatech has linked its GLP-1/glucagon dual receptor agonist to improvements in liver health, keeping the Korean ...

Pemvidutide improves fibrosis markers, liver fat, lipids, weight, and blood pressure in patients with MASH at 1 year, phase 2b data show.

D&D Pharmatech, Inc. (D&D) (KOSDAQ: 347850), a clinical-stage biotechnology company developing breakthrough treatments for liver and metabolic diseases, today announced positive top-line 48-week ...

Meena Bansal, MD, discusses the evolving MASH pipeline and why precision phenotyping, biomarkers, and cardiovascular outcomes ...

Altimmune announces IMPACT phase 2b data from pemvidutide; shows significant metabolic improvements in patients with MASH: Gaithersburg, Maryland Saturday, May 30, 2026, 16:00 Hrs ...

Add Yahoo as a preferred source to see more of our stories on Google. A Halloween conspiracy theory going viral on Twitter has social media users coming to a startling realization about Bobby ...

MASLD and Liver Cancer: What’s the Link? Metabolic dysfunction-associated steatotic liver disease (MASLD) is a condition where too much fat builds up in your liver. Unlike fatty liver caused by heavy ...

Growing body of clinical and real-world evidence supports the role of Rezdiffra® (resmetirom) as the foundational therapy for patients with MASH Rezdiffra improved atherogenic lipid profiles ...

What Are Clinical Trials for MASH? Clinical trials for MASH are research studies that evaluate potential new treatments for a form of liver disease called metabolic dysfunction-associated ...

Add Yahoo as a preferred source to see more of our stories on Google. “Monster Mash” by Bobby “Boris” Pickett and the Crypt-Kickers has just been crowned the biggest Halloween song of all time by ...